Search - tctmd.com

Displaying 21 - 40 of 105

Sort: Relevancy | Date

News Conference News TVT 2023

‘Excellent’ Outcomes With Mitral ViV Procedures, Even in Lower-Risk Patients

Michael O'Riordan

June 09, 2023

News Conference News THT 2023

More Early Insights Into Interatrial Shunts in HF, but Little to Focus the Field

Shelley Wood

March 24, 2023

Presentation THT 2023

Impella as a Bridge-to-Closure in Post-Infarction Ventricular Septal Defect

Presenter: Sandeep Jalli

March 21, 2023

News Daily News

Top Heart Failure News of 2022

Shelley Wood

January 04, 2023

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

L.A. McKeown

October 07, 2022

News Conference News TCT 2022

Both Surgical, Percutaneous Closure Boost Survival in Post-STEMI VSD

Shelley Wood

September 18, 2022

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Todd Neale

September 16, 2022

News Daily News

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Todd Neale

September 15, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Features

A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts

Shelley Wood

July 07, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

Shelley Wood

May 02, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Conference News THT 2022

LAVA ECMO: Early Data Point to Hemodynamic Benefits, Safety

Caitlin E. Cox

February 02, 2022

Presentation TCT 2021

TCT 713: A Case Of Septal Reduction With Tru-Septal RF Ablation Via Coronary Sinus (TIRA) In HOCM Patient: Representative Case of The First in Man Trial Of TIRA

Presenter: Min-Ku Chon

November 04, 2021

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

News Opinion Editor's Corner TCT 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

Shelley Wood

October 09, 2020

Advertisement

‘Excellent’ Outcomes With Mitral ViV Procedures, Even in Lower-Risk Patients

More Early Insights Into Interatrial Shunts in HF, but Little to Focus the Field

Impella as a Bridge-to-Closure in Post-Infarction Ventricular Septal Defect

Top Heart Failure News of 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

Both Surgical, Percutaneous Closure Boost Survival in Post-STEMI VSD

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

New Faces, New Formats, New Tech: What to Expect From TCT 2022

A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

TCTMD’s Top 10 Most Popular Stories for April 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

What’s Going to Be Hot at ACC 2022, In Person or Virtual

LAVA ECMO: Early Data Point to Hemodynamic Benefits, Safety

TCT 713: A Case Of Septal Reduction With Tru-Septal RF Ablation Via Coronary Sinus (TIRA) In HOCM Patient: Representative Case of The First in Man Trial Of TIRA

‘Enormous’ QoL Improvements With Mavacamten in HCM

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content